Targeted Reprogramming of TREM2‐Positive Macrophages and MRI‐Guided Immune Monitoring in Colorectal Cancer Using CSF1R@Mn@MPDA‐Antitrem2 Nanoplatform
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202501027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Jie Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Magnetic Resonance Imaging, Membrane Glycoproteins, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Taishan Scholars Program of Shandong Province.
Abstract (Originalsprache)
Colorectal cancer (CRC) poses a significant therapeutic challenge due to its immunosuppressive tumor microenvironmentl (TME). In this environment, triggering receptors expressed on myeloid cells 2 (TREM2+) tumor‐associated macrophages (TAMs) drive immune evasion and therapy resistance. In this study, CSF1R‐IN‐3@Mn@MPDA‐antiTREM2 (CMMT) is presented, a manganese‐doped mesoporous polydopamine nanoplatform conjugated with anti‐TREM2 antibodies, which integrates TAM reprogramming and magnetic resonance imaging (MRI)‐guided immune monitoring. CMMT has three key characteristics: 1) pH‐responsive release of the Colony Stimulating Factor 1 Receptor (CSF1R) inhibitor CSF1R‐IN‐3 within acidic TME; 2) selective targeting of TREM2+ M2 macrophages, achieving 4.2‐fold higher uptake compared to M1 subsets ( P < 0.001); and 3) dual modulation of TREM2 and CSF1R pathways, polarizing M2‐TAMs toward pro‐inflammatory M1 phenotypes. In orthotopic CRC models, CMMT synergizes with anti‐PD‐L1 therapy, reducing tumor volume by 72.5% compared to 42.1% for monotherapy ( P < 0.001). It also extends median survival from 28 to 52 days. Importantly, CMMT acts as an MRI contrast agent, with T1 signal intensity correlating with intratumoral TREM2+ macrophage density (r‐ 0.71, P < 0.05), enabling non‐invasive assessment of TME remodeling. This theranostic platform bridges immune modulation and real‐time monitoring, providing a promising strategy to overcome immunotherapy resistance in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
- Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, 250021, China.
- Department of Nuclear Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
- Department of Radiology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, No. 725, South Wanping Road, Shanghai, 200032, China.
ORCID-Profile: Huijie Jiang
Förderung
- National Natural Science Foundation of China
- Taishan Scholars Program of Shandong Province
Zitieren
APA
Zhao, J., Li, M., Wu, Q., Qiao, G., Jiang, H., Zhao, S., Zhang, L., Wang, S., & Jiang, H. (2025). Targeted Reprogramming of TREM2‐Positive Macrophages and MRI‐Guided Immune Monitoring in Colorectal Cancer Using CSF1R@Mn@MPDA‐Antitrem2 Nanoplatform. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202501027
Vancouver
Zhao J, Li M, Wu Q, Qiao G, Jiang H, Zhao S, et al. Targeted Reprogramming of TREM2‐Positive Macrophages and MRI‐Guided Immune Monitoring in Colorectal Cancer Using CSF1R@Mn@MPDA‐Antitrem2 Nanoplatform. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202501027
BibTeX
@article{Zhao2025,
author = {Zhao, Jie and Li, Ming and Wu, Qiong and Qiao, Guanzhong and Jiang, Hao and Zhao, Sheng and Zhang, Linhan and Wang, Song and Jiang, Huijie},
title = {Targeted Reprogramming of TREM2‐Positive Macrophages and MRI‐Guided Immune Monitoring in Colorectal Cancer Using CSF1R@Mn@MPDA‐Antitrem2 Nanoplatform},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202501027}
}
EUVIMED